Bleeding, vertebral fractures and vascular calcifications in patients treated with warfarin: Hope for lower risks with alternative therapies

Current Vascular Pharmacology

Volumn 9, Issue 6, 2011, Pages 763-769

  Fusaro, Maria ^a   Crepaldi, Gaetano ^a   Maggi, Stefania ^a   D'Angelo, Angela ^b   Calò, Lorenzo ^b   Miozzo, Davide ^b   Fornasieri, Alessandro ^c   Gallieni, Maurizio ^c  

^a CNR   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

Atrial fibrillation; Bleeding; Bone fractures; Coagulation; Dabigatran; Osteoporosis; Rivaroxaban; Vascular calcification; Warfarin

Indexed keywords

ANTIVITAMIN K; CYTOCHROME P450 2C9; DABIGATRAN; ENOXAPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCALCIN; RIVAROXABAN; VITAMIN K DEPENDENT CARBOXYLASE; WARFARIN; XIMELAGATRAN;

ACUTE HEART INFARCTION; ALCOHOLISM; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD VESSEL CALCIFICATION; BONE MINERALIZATION; CHRONIC KIDNEY FAILURE; DYSPEPSIA; FRACTURE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; KIDNEY FAILURE; MITRAL VALVE STENOSIS; MORBIDITY; MORTALITY; OSTEOPOROSIS; SKIN NECROSIS; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VITAMIN K DEFICIENCY;

ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG DESIGN; DRUG MONITORING; HEMORRHAGE; HUMANS; SPINAL FRACTURES; THROMBOEMBOLISM; VASCULAR CALCIFICATION; VITAMIN K; WARFARIN;

EID: 80054070913     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111797484134     Document Type: Article

References (70)

1. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: e269-e367.
2. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-41.
3. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.
4. Murphy NF, Simpson CR, Jhund PS, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart. 2007; 93: 606-12.
5. Bilato C, Corti MC, Baggio G, et al. Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro.V.A. study). Am J Cardiol 2009; 104: 1092-7.
6. Atta MG. Atrial fibrillation in dialysis patients: a neglected comorbidity. J Am Soc Nephrol. 2011; 22: 203-5.
7. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in haemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77: 1098-106.
8. Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term haemodialysis patients. Am J Kidney Dis 2005; 46: 897-902.
9. Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S. The increasing prevalence of atrial fibrillation (AF) among hemodialysis patients. J Am Soc Nephrol 2011; 22: 349-57.
10. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
11. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillationexecutive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006; 27: 1979-2030. Erratum in: Eur Heart J 2007; 28: 2046.
12. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based ap proach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-72.
13. Olesen JB, Lip GY, Hansen ML, et al. Validation of Risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124.
14. To AC, Yehia M, Collins JF, et al. Atrial fibrillation in haemodialysis patients: do the guidelines for anticoagulation apply? Nephrology (Carlton) 2007; 12: 441-7.
15. Bos WJ, van Manen JG, Noordzij M, et al. Is the inverse relation between blood pressure and mortality normalized in 'low-risk' dialysis patients? J Hypertens 2010; 28: 439-45.
16. Vazquez E, Sanchez-Perales C, Garcia-Garcia F, et al. Atrial fibrillation in incident dialysis patients. Kidney Int 2009; 76: 324-30.
17. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-9.
18. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting haemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-9.
19. Ruíz-Giménez N, Suárez C, González R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 26-31.
20. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173-80.
21. Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging 2009; 4: 165-77.
22. No authors listed. Warfarin vs. aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91.
23. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20: 705-11.
24. Holden RM, Harman GJ, Wang M. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 105-10.
25. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20: 912-21.
26. Vázquez E, Sánchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on haemodialysis. Am Heart J 2000; 140: 886-90.
27. Chan KE, Lazarus JM, Thadhani R, et al. Warfarin use associates with increased risk for stroke in haemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20: 2223-33.
28. Sood MM, Komenda P, Sood AR, Rigatto C, Bueti J. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on haemodialysis? Chest 2009; 136: 1128-33.
29. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7: 97-104.
30. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87: 445-51.
31. Krueger T, Westenfeld R, Ketteler M, Schurgers LJ, Floege J. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? Kidney Int 2009; 76: 18-22.
32. Ducy P, Desbois C, Boyee P, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382: 448-452.
33. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
34. Shearer MJ. Role of vitamin K and GLA proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care 2000; 3: 433-8.
35. Schurgers LJ, Aebert H, Vermeer C, et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease: Blood 2004; 104: 3231-2.
36. Kruegert T, Floege J. Coumarin use in dialysis patients with atrial fibrillation--more harm than benefit? Nephrol Dial Transplant 2009; 24: 3284-5.
37. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-1407.
38. Price PA, Faus SA, Williamson MK. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 2000; 20: 317-27.
39. Howe AM, Webster WS. Warfarin exposure and calcification of the arterial system in the rat. Int J Exp Pathol 2000; 81: 51-6.
40. Holden RM, Sanfilippo AS, Hopman WM, et al. Warfarin and aortic valve calcification in haemodialysis patients. J Nephrol 2007; 20: 417-422.
41. Koos R, Krueger T, Westenfeld R, et al. Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 2009; 101: 706-13.
42. Rennenberg RJ, van Varik BJ, Schurgers LJ, et al. Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood 2010; 115: 5121-3.
43. Ketteler M, Westenfeld R, Schlieper G, et al. Pathogenesis of vascular calcification in dialysis patients. Clin Exp Nephrol 2005; 9: 265-70.
44. Rodríguez-García M, Gómez-Alonso C, Naves-Díaz M, Díaz- López JB, Díaz-Corte C, Cannata-Andía JB, Asturias Study Group. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant 2009, 24: 239-46.
45. Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007; 56: 569-79.
46. Wang Y, Zhang W, Zhang Y, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006; 113: 1615-21.
47. Kohn MH, Price RE, Pelz HJ. A cardiovascular phenotype in warfarin- resistant Vkorc1 mutant rats. Artery Res 2008; 2: 138-147.
48. Schlieper G, Westenfeld R, Krüger T, et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011; 22: 387-95.
49. Gage BF, Birman E, Radford MJ. Risk of osteoporotic fracture in elderly patients taking warfarin: results from National Registry of Atrial Fibrillation 2. Arch Intern Med 2006; 23: 241-6.
50. Mamdani M, Upshur RE, Anderson G, et al. Warfarin therapy and risk of hip fracture among elderly patients. Pharmacotherapy 2003; 23: 1-4.
51. Riess H, Loew A, Himmelreich G. Secondary osteoporosis induced by anticoagulants. Orthopade 2001; 30: 451-5.
52. Booth SL, Mayer J. Warfarin use and fracture risk. Nutr Rev 2000; 58: 20-2.
53. Fusaro M, D'Angelo A, Gallieni M. Vertebral fractures in patients on dialysis: a clinically relevant problem with insufficient investigation. NDT Plus 2008; 1: 464-5.
54. Fusaro M, D'Angelo A, Scalzo G, et al. Vertebral fractures in dialysis: Endocrinological disruption of the bone-kidney axis. J Endocrinol Invest. 2010; 33: 347-52.
55. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 57: 1330-7.
56. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-95.
57. Fusaro M, Crepaldi G, Maggi S, et al. Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: an important but poorly studied relationship. J Endocrinol Invest 2011; 34: 317-23.
58. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-68.
59. Pradaxa: European Public Assessment Report (EPAR) - Product information. Annex 1. Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed on May 22, 2011
60. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85.
61. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate vs. enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.
62. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
63. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-6.
64. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362: 789-97.
65. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-83.
66. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban vs. enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2776-86.
67. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban vs. short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind randomised controlled trial. Lancet 2008; 372: 31-9.
68. Rocket AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF Study. Am Heart J 2010; 159: 340-347.
69. Cleland JG, Coletta AP, Buga L, et al. Clinical trials update from the American Heart Association Meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF and PROTECT. Eur J Heart Fail 2011; 13: 460-5.
70. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010; 70: 703-12.